Primary MR Management Algorithm

 PRIMARY MITRAL REGURGITATION MANAGEMENT

Clinical Guide for Physicians

---

WHAT IS PRIMARY MITRAL REGURGITATION?

Primary Mitral Regurgitation (MR) occurs when the mitral valve apparatus itself is structurally abnormal, leading to backflow of blood from the left ventricle to the left atrium during systole.

Common causes include:

• Mitral valve prolapse

• Degenerative mitral valve disease

• Flail leaflet due to chordae rupture

• Rheumatic disease

• Infective endocarditis

• Congenital cleft mitral valve

The severity of regurgitation determines management strategy.

---

CLASSIFICATION

Primary MR is classified based on severity and symptoms.

Mild MR

Small regurgitant jet with no hemodynamic impact.

Moderate MR

Larger jet but without significant LV remodeling.

Severe MR

Characterized by:

• Regurgitant volume ≥ 60 ml

• Regurgitant fraction ≥ 50%

• Effective regurgitant orifice area (EROA) ≥ 0.40 cm²

---

CLINICAL PRESENTATION

Patients may present with:

• Dyspnea on exertion

• Fatigue

• Palpitations (due to atrial fibrillation)

• Orthopnea in advanced disease

On examination:

• Holosystolic murmur at the apex

• Murmur radiating to axilla

• Displaced apical impulse in chronic severe MR

---

DIAGNOSTIC EVALUATION

Transthoracic Echocardiography (TTE) is the cornerstone of diagnosis.

Key parameters assessed:

• Mechanism of MR

• Severity of regurgitation

• LV size and function

• Left atrial size

• Pulmonary pressures

Transesophageal Echo (TEE)

Used when TTE is inconclusive or for surgical planning.

Cardiac MRI

Helpful in quantifying MR severity when echo findings are uncertain.

---

MEDICAL MANAGEMENT

There is no specific medical therapy that corrects primary MR, but medications help manage symptoms and complications.

Common therapies include:

• Diuretics – relieve pulmonary congestion

• Beta blockers – useful in atrial fibrillation

• ACE inhibitors / ARBs – used if LV dysfunction develops

• Anticoagulation – indicated if atrial fibrillation is present

Medical therapy does not halt progression of degenerative MR.

---

INDICATIONS FOR SURGERY (ACC/AHA GUIDELINES)

Surgery is recommended in severe primary MR under the following conditions.

Class I Indications

• Symptomatic severe MR with LVEF >30%

• Asymptomatic severe MR with LV dysfunction

LVEF ≤60%

LVESD ≥40 mm

Class IIa Indications

• Asymptomatic severe MR with preserved EF but:

New onset atrial fibrillation

Pulmonary hypertension (PASP >50 mmHg)

---

MITRAL VALVE REPAIR VS REPLACEMENT

Mitral Valve Repair (Preferred)

Advantages:

• Better survival

• Preserves LV function

• Lower risk of prosthetic complications

• No long-term anticoagulation (usually)

Repair is recommended whenever feasible in degenerative MR.

Mitral Valve Replacement

Used when repair is not possible due to:

• Extensive leaflet damage

• Severe calcification

• Rheumatic disease

---

TRANSCATHETER EDGE-TO-EDGE REPAIR

For patients who are high surgical risk, percutaneous treatment can be considered.

The most widely used device is:

MitraClip

Indications include:

• Severe symptomatic MR

• Prohibitive surgical risk

• Favorable valve anatomy

This therapy approximates the mitral leaflets to reduce regurgitation.

---

FOLLOW-UP AND SURVEILLANCE

Patients with primary MR require periodic echocardiographic follow-up.

Recommended intervals:

Mild MR — every 3–5 years

Moderate MR — every 1–2 years

Severe asymptomatic MR — every 6–12 months

Monitoring focuses on:

• LV size and function

• Symptom development

• Pulmonary pressures

• Atrial fibrillation

---

KEY CLINICAL PEARLS

• Early surgery is recommended before irreversible LV dysfunction develops.

• LVEF ≤60% already indicates LV dysfunction in MR.

• Mitral valve repair is superior to replacement whenever feasible.

• Echocardiography remains the most important tool for monitoring progression.

• Transcatheter therapies are expanding options for high-risk patients.

---

Drmusmanjaved.com